See more : eve Sleep plc (EVE.L) Income Statement Analysis – Financial Results
Complete financial analysis of Glow Lifetech Corp. (GLOW.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Glow Lifetech Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Nordea Invest Basis 2 (NDIB2KL1.CO) Income Statement Analysis – Financial Results
- Feng Hsin Steel Co., Ltd. (2015.TW) Income Statement Analysis – Financial Results
- PainChek Limited (PCK.AX) Income Statement Analysis – Financial Results
- Speqta AB (publ) (SPEQT.ST) Income Statement Analysis – Financial Results
- JD Bancshares, Inc. (JDVB) Income Statement Analysis – Financial Results
Glow Lifetech Corp. (GLOW.CN)
About Glow Lifetech Corp.
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical and cannabis nutrient delivery technology; and a cannabis Smart Consumption System to assist users and patients to store, journal, control, consume, and manage cannabis related products. The company has the exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K, and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company was incorporated in 2018 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 43.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.88K | 588.65K | 43.39K | 0.00 | 0.00 |
| Gross Profit | 10.06K | -588.65K | -43.39K | 0.00 | 0.00 |
| Gross Profit Ratio | 22.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 172.74K | 127.41K | 0.00 | 0.00 | 265.49 |
| General & Administrative | 978.95K | 1.54M | 5.15M | 153.48K | 182.77K |
| Selling & Marketing | 56.15K | 39.51K | 86.73K | 110.49 | 103.00 |
| SG&A | 1.04M | 1.58M | 5.23M | 153.48K | 182.77K |
| Other Expenses | 463.22K | 588.65K | 43.39K | 0.00 | 126.64K |
| Operating Expenses | 25.72K | 2.30M | 5.28M | 153.48K | 182.77K |
| Cost & Expenses | 1.69M | 2.30M | 5.28M | 153.48K | 182.77K |
| Interest Income | 0.00 | 2.89 | 4.29 | 5.57 | 0.03 |
| Interest Expense | 13.69K | 2.89K | 4.29K | 0.00 | 0.00 |
| Depreciation & Amortization | 368.88K | 588.65K | 43.39K | 1.49M | 796.16K |
| EBITDA | -1.26M | -1.71M | -4.59M | -153.48K | 740.02K |
| EBITDA Ratio | -2,875.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.64M | -2.30M | -5.28M | -153.48K | -182.77K |
| Operating Income Ratio | -3,739.30% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.90K | -304.33K | -6.72M | 0.00 | 126.64K |
| Income Before Tax | -1.65M | -2.27M | -11.31M | -153.48K | -56.14K |
| Income Before Tax Ratio | -3,745.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -27.91K | 4.29K | -1.49K | -796.16 |
| Net Income | -1.65M | -2.24M | -11.32M | -153.48K | -56.14K |
| Net Income Ratio | -3,745.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.04 | -0.20 | -0.03 | -0.01 |
| EPS Diluted | -0.03 | -0.04 | -0.20 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 57.11M | 57.11M | 57.11M | 4.67M | 4.67M |
| Weighted Avg Shares Out (Dil) | 57.11M | 57.11M | 57.11M | 4.67M | 4.67M |
Source: https://incomestatements.info
Category: Stock Reports